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Vinyl chloride (VC) is a colourless toxic gas used extensively in
the plastic industry as a refridgerant and an intermediate in organic
synthesis. VC is rapidly absorbed following respiratory exposure
and is primarily metabolized in the liver via the microsomal
cytochrome P450 monooxygenase system to the electrophilic
metabolites: chloroethylene oxide (CEO) and chloroacetaldehyde
(CAA) (el Ghiassassi et al, 1998). CEO and CAA react with DNA
bases to form mutagenic adducts in bacterial and mammalian cells
(Thompson et al, 1985; Barbin, 1999). In humans, a causal rela-
tionship has been demonstrated between occupational exposure
to VC and liver angiosarcomas (LAS) (Tamburro et al, 1984;
Hollstein et al, 1994). In 1983 Evans et al reported 2 cases of hepa-
tocellular carcinomas (HCC) among VC workers (Evans et al,
1983). Several epidemiological studies again reported this associa-
tion in humans (Trivers et al, 1995; Marion et al, 1996). Increased
morbidity odds ratios of HCC among VC workers were recently
described (Du and Wang, 1998). However, in cohort studies,
primary HCC and LAS are not always delineated, and the status of
the adjacent non-neoplastic liver tissue is not available in most
reported data (Heldaas et al, 1984). Exact data concerning the
amount of VC exposure have not been presented within the studies
published. Current literature demonstrates mutation analysis of the
proto-oncogene ras has been analysed in LAS due to VC (DeVivo
et al, 1994; Luo et al, 1998) and in animal models (Soman and
Wogan, 1993; Froment et al, 1994; Barbin et al, 1997; Boivin-
Angele et al, 2000); yet, no published data are available for human
HCCs associated with VC exposure. After ras, one of the earliest
and most potent oncogenes identified in human cancer, the tumour
suppressor gene p16 is one of the most frequently altered genes
observed in various malignancies (Xing et al, 1999). The p16 gene
product encodes a negative regulatory protein preventing the cell
cycle progression from G1 to S-phase (Roussel, 1999). Inactivation
of  p16 may cause abnormal cell cycles and uncontrolled cell
growth (Huschtscha and Reddel, 1999). Recent data have indic-
ated inactivation of p16 in HCC is due to de novo hypermethyla-
tion of the 5¢-promotor-associated CpG island (Liew et al, 1999).
Introduction of ras mutations in vivo into cells deficient in p16
(INK4a) is sufficient to induce characteristics of cellular trans-
formation such as tumour formation (Gressani et al, 1998; Pantoja
and Serrano, 1999; Rodrigues-Puebla et al, 1999). Data from K-
ras transformation studies suggest that K-ras mutations induce
p16 hypermethylation and inactivation of p16 (MacLeod et al,
1995; Serrano et al, 1995; Wadhwa et al, 2000). 
To analyse the K-ras-2 oncogene and its possible association
with p16 methylation status, we examined tissue from 18 patients
with resected HCCs and known VC exposure. All patients had
received financial compensation after extensive assessment to
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Summary Vinyl chloride (VC) is a know animal and human carcinogen associated with liver angiosarcomas (LAS) and hepatocellular
carcinomas (HCC). In VC-associated LAS mutations of the K-ras-2 gene have been reported; however, no data about the prevalence of such
mutations in VC associated HCCs are available. Recent data indicate K-ras-2 mutations induce P16 methylation accompanied by inactivation
of the p16 gene. The presence of K-ras-2 mutations was analysed in tissue from 18 patients with VC associated HCCs. As a control group,
20 patients with hepatocellular carcinoma due to hepatitis B (n = 7), hepatitis C (n = 5) and alcoholic liver cirrhosis (n = 8) was used. The
specific mutations were determined by direct sequencing of codon 12 and 13 of the K-ras-2 gene in carcinomatous and adjacent non-
neoplastic liver tissue after microdissection. The status of p16 was evaluated by methylation-specific PCR (MSP), microsatellite analysis,
DNA sequencing and immunohistochemical staining. All patients had a documented chronic quantitated exposure to VC (average 8883
ppmy, average duration: 245 months). K-ras-2 mutations were found in 6 of 18 (33%) examined VC-associated HCCs and in 3 cases of
adjacent non-neoplastic liver tissue. There were 3 G ® A point mutations in the tumour tissue. All 3 mutations found in non-neoplastic liver
from VC-exposed patients were also G ® A point mutations (codon 12- and codon 13-aspartate mutations). Hypermethylation of the 5¢ CpG
island of the p16 gene was found in 13 of 18 examined carcinomas (72%). Of 6 cancers with K-ras-2 mutations, 5 specimens also showed
methylated p16. Within the control group, K-ras-2 mutation were found in 3 of 20 (15%) examined HCC. p16 methylation occurred in 11 out of
20 (55%) patients. K-ras-2 mutations and p16 methylation are frequent events in VC associated HCCs. We observed a K-ras-2 mutation
pattern characteristic of chloroethylene oxide, a carcinogenic metabolite of VC. Our results strongly suggest that K-ras-2 mutations play an
important role in the pathogenesis of VC-associated HCC. © 2001 Cancer Research Campaign http://www.bjcancer.com
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prove the association of their cancer with VC exposure. As a
control group, hepatocellular carcinoma tissue from 20 patients
with chronic hepatitis B and C virus infection and alcohol-induced
cirrhosis with HCC was used. The presence of K-ras-2 mutations
was examined by direct sequencing after microdissection of the
tumour nodules. 
MATERIALS AND METHODS 
Patients and tissue samples 
Data were extracted from the German industrial professional asso-
ciation for the chemical industry which is responsible for statutory
accident insurance and provides medical and social rehabilitation
and financial compensation to persons who incur an industrial
injury or occupational disease. According to the German social
legislation code VII, compensation for work-related impairment
and disability is only possible in cases of a proven association
of occupational factor and disease. The criteria for the patients
included in this study were a documented chronic quantitated
exposure to VC, which leads to compensation under the German
social legislation code VII (Table 1). Estimates of VC exposure
were based on years worked with VC and estimated ppm years
of VC exposure. Based on the exposure matrix of Heldaas et al
(1984) for production, autoclave cleaning, maintenance and
packing/drying job categories, exposures averaged 2000 ppm from
1950 through 1954, 1000 ppm from 1955 through 1959, 500 ppm
from 1960 through 1967, 100 ppm from 1968 through 1974 and 1
ppm thereafter. 18 patients diagnosed with HCC who had under-
gone partial hepatectomy between 1981 and 1997 were identified
and included all males with an average age of 62 years (49 to 75 y)
and an average exposure to VC of 245 months (124 to 416
months). The average amount of exposure to VC was 8883 ppm
(range 3600–20 000 ppm) and occurred between 1935 to 1984. The
latency period between first exposure and the initial histological
diagnosis of HCC varied between 10 and 25 years with a median
latency of 18 years. 
All other aetiologies of HCC were excluded by clinical history,
laboratory serological examination and immunohistochemical 
analysis. 
As a control group, 20 patients with hepatocellular carcinoma –
most certainly without VC exposure – were analysed. These hepato-
cellular carcinomas had a known, clinically and serologically
defined aetiology. They were attributed to chronic hepatitis B (n =
7) and hepatitis C virus infection (n = 5). 8 patients with liver
cirrhosis after long-term alcohol consumption and HCC were also
included in the control group (Table 2). 
Formalin-fixed blocks of tissue with tumour and adjacent non-
neoplastic liver tissue was available for analysis. All tumours were
diagnosed as HCCs. Each tumour was re-evaluated with regard to
typing, staging and grading (WHO, 1994; UICC, 1997 ). Tumour
typing and staging was performed using WHO and UICC (1997)
criteria. 
DNA samples 
For each HCC sample, the lesions were first identified on
routinely stained haematoxolin and eosin slides (H&E).
Additional sections were cut from the paraffin blocks with a
microtome set at 6 mm, and dried on slides overnight at 37˚C.
Tumour and adjacent non-neoplastic tissue was identified and
microdissected after rapid staining with H&E. The tissue was
removed from the slide under solution (25 ml Tris buffer, 0.05
mol) with the tip of a sealed glass pipette and then evacuated
into a microcapillary. The samples were transferred to
Eppendorf tubes and incubated with proteinase K at 37˚C
overnight. Proteinase K activity was inactivated by heating to
95˚C for 10 min, and the resulting solutions were used directly
as templates for K-ras analyses. Following proteinase K incuba-
tion, the DNA was extracted in standard fashion, twice in
Table 2 Patients data of the control group 
Case no. Age (y) UICC – Stage Aetiology Histopathological diagnosis K-ras-2 status p16 status 
Carcinoma Non-neoplastic 
liver tissue 
1 67 IIIA Hepatitis B well diff. HCC without cirrhosis wild type wild type methylated 
2 78 II Hepatitis B mod.diff. HCC in cirrhosis wild type wild type wt 
3 49 I Hepatitis B mod. diff. HCC without cirrhosis mutant wild type wt 
4 76 IIIB Hepatitis B mod.diff. HCC without cirrhosis wild type wild type wt 
5 57 IVA Hepatitis B well diff. HCC in cirrhosis mutant mutant methylated 
6 34 II Hepatitis B poorly diff. HCC without cirrhosis wild type wild type methylated 
7 59 IIIA Hepatitis B well diff. HCC without cirrhosis wild type wild type methylated 
8 54 IIIB Hepatitis C mod.diff. HCC without cirrhosis wild type wild type LOH 
9 63 II Hepatitis C well diff. HCC in cirrhosis wild type wild type methylated 
10 71 IIIB Hepatitis C mod.diff. HCC in cirrhosis mutant wild type wt 
11 58 IVA Hepatitis C well diff. HCC without cirrhosis wild type wild type methylated 
12 80 IIIB Hepatitis C mod.diff. HCC without cirrhosis wild type wild type methylated 
13 55 II Alcohol consumption mod.diff. HCC in cirrhosis wild type wild type methylated 
14 51 I Alcohol consumption poorly diff. HCC in cirrhosis wild type wild type methylated 
15 65 IIIA Alcohol consumption mod.diff. HCC without cirrhosis wild type wild type wt 
16 62 IIIA Alcohol consumption well. diff. HCC in cirrhosis wild type wild type methylated 
17 72 II Alcohol consumption mod.diff. HCC in cirrhosis wild type wild type wt 
18 75 IIIB Alcohol consumption well diff. HCC in cirrhosis wild type wild type wt 
19 61 IVA Alcohol consumption well diff. HCC in cirrhosis wild type wild type methylated 
20 52 IIIB Alcohol consumption mod.diff. HCC in cirrhosis wild type wild type LOH 
aLOH: with the two markers D9S 1751 and D9S171. wt = wild type. K-ras-2 and p16 in vinyl chloride associated HCC 985
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phenol and twice in chloroform, then followed by ethanol
precipitation. 
K-ras-2 mutation analysis 
All pre-PCR tissue was handled in an environment free of PCR
products. All samples were coded and the investigator was blinded
to all patients’ clinical details. De-paraffinized tissue was re-
covered with 2 cycles each of a 15 min incubation with xylene
followed by centrifugation for 5 minutes at 14 000 rpm. The tissue
pellet was washed twice in absolute ethanol and twice in phos-
phate buffered saline. The pellet was incubated with 10 pellet
volumes (approximately 500 ml) of lysis buffer (0.32 M sucrose,
10 mM Tris-HCl, 1% (v/v) Triton X-100) and 0.2 volumes of
proteinase K (final concentration 400 mgm l –1) for 2 to 3 days at
37˚C. DNA was phenol-chloroform extracted and precipitated in
ethanol using conventional techniques (Bjorheim et al, 1998). The
resulting DNA pellet was resuspended in 50 ml TE buffer, pH 7.4,
(10 mM Tris-HCl, pH 7.4, 1 mM EDTA, pH 8.0). DNA samples
were stored at 20˚C. 
The first exon of K-ras-2 was amplified by PCR using primers
designed to avoid amplification of the K-ras pseudogene (Bautista
et al, 1997; Bjorheim et al, 1998). The primers were 
5¢-ATTATAAGGCCTGCTGAAAATG-ACTGA-3¢ (upstream
primer) and 5¢-ATATGCATATTAAAACAAGATTTACCT-CTA-
3¢ (downstream primer) which yield a 155 base-pair product.
Amplification was performed using a PCR technique (Bjorheim
et al, 1998) from 63˚C to 53˚C over 10 cycles, followed by 30
cycles at 94˚C, 53˚C and 72˚C. PCR products were purified using
the Qiaquick PCR purification kit (Qiagen, Hilden, Germany) and
sequenced using dye primer cycle sequencing and AmpliTaq poly-
merase FS on an Applied Biosystems 373 DNA sequencer (ABI
373; Applied Biosystems-Perkin-Elmer/Cetus, Norwalk). 
Controls 
DNA from colon carcinoma cell lines SW480 (Clontech, Palo
Alto, California, USA) and HCT116 (American Type Culture
Collection, ATCC, Rockville, Maryland, USA) with known 
K-ras-2 mutations at codon 12 (GTT) and codon 13 (GAC)
respectively, were used as positive controls in each of the parallel
procedures. Negative controls, without DNA, were run as controls
for contamination. 
If a mutation was detected, confirmation by amplification and
sequencing of a fresh DNA sample using the upstream primer was
performed. Any sequences which proved difficult to read were re-
amplified and re-sequenced. 
Methylation specific PCR (MSP) 
The CpG WIZ p16 Methylation Assay Kit was used (OncorInc,
Gaithersburg, MD, USA) according to the manufacturers
instructions. After an initial bisulphide reaction to modify the
DNA, a PCR amplification with specific primers was performed
to distinguish methylated from unmethylated DNA. Primers were
specific for the unmethylated p16 (5- TTATTAGAGGGTGGGGT-
GGATTGT-3, 5-CAACCCCAAACCACAACCATAA-3) or the
methylated p16 (5-TTATTAGAGGGTGGGGCGGATCGC-3, 5-
GACCCCGAACCGCGACCGTAA-3). A sample of 7 mg 100
ml–1 DNA was denaturated by NaOH, 0.2M, for 10 min at room
temperature. DNA Modification Reagent I was added, incubated
for 24 h at 50˚C and subsequently purified by DNA Modification
Reagent II and III in the presence of 50 ml water. The bisulphate
modification of DNA was completed with 0.3M NaOH treatment
for 5 min, followed by ethanol precipitation. For hot start PCR,
the PCR mixture contained Universal PCR Buffers (1X9, 4dNTP’s
(1.25 nM), U or M primers (300 ng each per reaction)). Annealing
temperature was 65˚C for 35 cycles. The PCR product was directly
electrophoresed on a 3% agarose gel, stained with ethidium bromide
and visualized under UV illumination. Bisulphite-converted DNA
from adjacent non-neoplastic liver tissue from each patient served
as a negative control indicated by the presence of the unmethy-
lated but not the methylated band. 
Microsatellite analysis of the loss of heterozygosity
(LOH) 
We utilized 9 microsatellite markers flanking the region of chromo-
some 9p21 region where p16 is located. They were D9S161,
D9S126, D9S171, D9S1752, D9S1748, D9S1747, D9S1749,
D9S1751, and IFNA obtained from Research Genetics (Huntsville
AL, USA). The primers were labelled with 32P-ATP. PCR ampli-
fication was performed in a 10 ml reaction volume including 30 ng
genomic DNA, 10 mM TrisHCl, 50 mM KCl, 1.5 mM MgCl2, 62.5
mM deoxynucleotide triphosphate, 0.1 U Taq DNA-polymerase
and 1 pmol of each primer. A total of 45 cycles was performed with
annealing temperatures of 53˚ and 55˚C. PCR products were subse-
quently electrophoresed, dried and autoradiographed. Homozygous
deletion of the p16 gene was confirmed by comparative PCR
involving the amplification of 2 different sets of primer pairs in the
same reaction mixture. For homozygous deletions, the control
marker D9S126 was used. Homozygous deletion was scored if the
signal intensity (assessed by visual examination and densitometer)
of the p16 in tumour tissues was at least 10-fold less than the
signal from the non-neoplastic tissues. The intensity of the
D9S126 control allele was approximately equal in tumour and
adjacent non-neoplastic liver. 
DNA-sequencing of the p16 gene 
For mutation analysis on exon 1, 2 (2A, 2B, and 2C) and 3, SSCP
analysis was employed using the primers described by Hussussian
et al (1994). The SSCP analysis was performed as previously
described (Tannapfel et al, 1999a). The primers were labelled with
32P-ATP and each sample underwent PCR analysis (denaturing for
30 s, annealing for 45 s, extension for 30 s at 94˚C, 55–60˚C and
72˚C respectively). The PCR products were electrophoresed, the
gels dried and autoradiographed. Variant SSCP bands were cut out
from the gel and the DNA eluted. Variants bands and 3 ml of the
eluted DNA were used as template for unlabelled PCR. After
purification of the PCR products, sequencing analysis was
performed using the DNA-Sequenase-Kit (Amersham, Germany)
and an automatic sequencing analyser (ABI 373; Applied Bio-
systems-Perkin-Elmer, Germany). All mutations found were
confirmed by direct sequencing of the amplified tumour and adja-
cent non-neoplastic DNA to identify germline mutations and poly-
morphisms. The sequences of all primers used for amplification
are available from the authors upon request. 986 M Weihrauch et al 
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Immunohistochemical analysis 
The immunohistochemical analysis was performed as previously
described (Tannapfel et al, 1999b). In all cases, tumour and non-
neoplastic liver tissue was examined. The following antibodies
were used: ras (ras, monoclonal Clone F132; mouse, dilution:
1:120; final concentration: 10 mg ml–1, BoehringerR Mannheim,
Germany), p16 (polyclonal; rabbit, dilution 1:500, PharmingenR,
San Diego, CA), AFP (polyclonal; rabbit, dilution 1:300, DianovaR,
Hamburg, GERMANY), Hepatitis B (HBs-Ag, dilution: 1:80,
Dako-DiagnostikR, Hamburg, Germany), and Hepatitis C (HCV,
Clone TORDJ1-22, dilution: 1:200, BioGenexR, Hamburg,
Germany). Positive controls of antigen-containing tissue were
included in each batch. Negative controls, which had the primary
antibody replaced by mouse or goat ascites fluid, were also
included (Sigma-Aldrich Biochemicals, St Louis, MO). 
RESULTS 
K-ras-2 status 
PCR amplification and DNA sequencing enabled detection of
heterozygous mutations in 6 of 18 VC-HCCs (33%). 4 patients (22%)
had a mutation of codon 12 and 2 of codon 13. None showed multiple
mutations. In 3 cases (17%), mutation of the K-ras-2 gene was
detected in adjacent non-neoplastic liver tissue; 2 mutations occurred
in codon 13 and one was found in codon 12. In patient No 9 (Table 3),
a mutation occurred in cirrhotic liver tissue, while the tumour 
exhibited a wild type K-ras-2. The base pair change consisted of a
GGC ® CAT mutation which lead to a substitution of glycine for
aspartatic acid. We failed to observe an association between K-ras-2
mutation pattern and duration or amount of VC exposure. 
Within the 20 HCCs of the countrol group, specific K-ras-2
mutation were found in 3 cases (15%). 2 cases were attributed to
chronic hepatitis B virus infection (GGT ® GTT and GGC ®
GAC). In one case, the hepatocellular carcinoma arrised within a
hepatitis C virus-infected liver (GGT ® TGT). K-ras-2 mutations
were also detected in liver cirrhosis attributed to hepatitis B virus
infection (GGC ® TGC) (Table 2). 
Performing a semiquantitative assessment of p21ras immuno-
reactivity, neither the staining intensity nor the number of positive
cells correlated to the mutation pattern or to other histo-pathological
parameters (Table 3). Non-neoplastic liver tissue was occasionally
positive for p21ras. 
p16 alterations 
The methylation-specific PCR demonstrated aberrant methylation at
the 5¢ CpG island of the p16 gene in 13 of 18 (72%) VC-associated
carcinomas (Table 3, Figure 1). Despite microdissection, amplifica-
tion of unmethylated templates were detected most likely due to
contaminating normal intratumorous tissue (fibroblasts, endothelial
Table 3 K-ras-2 mutations and p16 methylation status in VC-associated hepatocellular carcinoma 
Case Stage Grade Codon Mutation substitution  Amino acid p21ras IHCa p16 methylation b
Codon 12  GGT (wild type) glycine
3 IVA 2 12 GGT®GAT aspartate ++ ++ 
5 IIIA 1 12 GGT®GTT valine ++ ++ 
10 IIIB 2 12 GGT®TGT cystine ++ – 
12 IIIB 2 12 GGT®GAT aspartate + ++ 
Codon 13  GGC (wild type) glycine
11 II 1 13 GGC®TGC cystine ++ ++ 
18 IVA 2 13 GGC®GAT aspartate + ++ 
5 non-neoplastic tissue 12 GGT®GAT aspartate + –
9 non-neoplastic (cirrhotic) tissue 13 GGC®CAT aspartate + – 
11 non-neoplastic tissue 13 GGC®GAC aspartate ++ – 
aras immunohistochemistry (IHC): positivity assessment according to the literature (Thor et al, 1986): negative (–) <1% positive nuclei; weakly positive (+):
single positive cells (10–30%); moderately positive (++): numerous positive cells (30–60%); strongly positive (+++): more than 60% positive tumour cells. 
bp16 methylation status: ++ methylation detection; — not detected. 
control
UM
T9 - 1 - T9 - 2 -
UM U M
NT
UM
case No 9
B A
Figure 1 Methylation analysis of p16 in hepatocellular carcinomas
associated with VC. MSP results are expressed as unmethylated p16-
specific bands (U) or methylated p16-specific bands (M). (A) Bisulfite-
converted DNA from normal liver tissue (N) served as a negative control as
indicated by the presence of the U but not the M band. (B) MSP results of
case No. 9. Two tumour-nodules (T9–1- and T9–2-) with methylated p16. The
tumour surrounding non-neoplastic liver tissue (NT) with unmethylated p16.
(C) Representative cases of VC-associated hepatocellular carcinoma. The
numbers of the hepatocellular carcinomas are shown above the
corresponding lanes and are identical to Tables 1 and 2 
control
UM UM UM
T5 T4 T3 T2 T1
UMUM UM
UM UM
T10 T9 T8 T7 T6
UM UM U M
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cells, inflammatory cells). In corresponding non-neoplastic liver
tissue, methylated templates were amplified in one case. This
patient exhibited a cirrhosis with a high degree of inflammation. Of
6 carcinomas with K-ras-2 mutations, 5 specimens also showed
methylated p16 (Table 3). All 13 cases with aberrant methylation of
the p16 gene showed a complete loss of immunoreactivity to p16
protein within the tumour tissue (Figure 2A). In 4 cases without a
methylated p16 promotor defined by methylation-specific PCR, a
nuclear staining of p16 protein was observed in nearly all tumour
cells with a moderate to high intensity of immunoreactivity (Figure
2B). In normal liver tissue, p16 protein was detected in all cases.
One HCC showed LOH in at least one locus on chromosome 9p21.
The highest frequency of LOH was observed with the microsatellite
marker D9S 1751 (3 cases) and the lowest with D9S171 (one case).
Homozygous deletion of the p16 gene was not observed. We failed
to observe specific mutations of the p16 gene. In SSCP analysis, a
mobility shift was detected in one carcinoma, however, we did not
find a specific mutation of p16 in this tumour. 
11 out of 20 hepatocellular carcinomas of the control group
(55%) exhibited a methylated p16 promotor (Table 2). Immuno-
histochemistry revealed a p16 protein loss of these cases. 2 HCC
of this group showed LOH in at least one marker. We failed to
identify homozygous deletion of the p16 locus. 
Histopathological features 
The pathological data (stage and grade) of VC-associated HCC are
summarized in Tables 1 and 3. Within the adjacent non-neoplastic
liver tissue, histopathological changes associated with VC exposure
were observed to a variable degree. In the 15 non-cirrhotic cases, a
moderate, predominantly microvesicular steatosis was present with
homogeneous distribution within the liver acinus. In 8 of these cases,
an interstitial and perivenular fibrosis was observed. Generally, a
mild non-specific mesenchymal inflammatory reaction occurred with
an increased number of Kupffer cells and prominent sinus endo-
thelial cells. In 5 cases, a marked sinusoidal dilatation was observed
resembling foci of peliosis. In one case we observed a local portal
phlebitis. We failed to observe a significant correlation between the
extent of histopathological liver damage and duration of exposure. 
Immunohistochemical analysis revealed AFP immunoreactivity
in 12 of 18 HCC (67%). All cases were negative for HBs-, or HBc-
or HCV-antigen expression within the non-neoplastic liver tissue
as well as within the tumour. 
DISCUSSION 
Liver angiosarcomas (LAS) were the first proven primary liver
tumours encountered in workers exposed to VC, while to date only
few HCCs in workers exposed to VC have been reported (Saurin
et al, 1997). Saurin et al have reported 2 histologically proven
cases of HCC after VC exposure. A recently published cohort
study on workers with chronic exposure to VC reported a signifi-
cant increase in primary liver cancer (Du and Wang, 1998). In that
data, the risk of developing a HCC increased with the total cumu-
lative exposure and the time since first exposure. Published studies
have to date not excluded the classic risk factors for HCCs. Based
on data recruited from the German industrial professional associ-
ation for the chemical industry, we examined 18 patients with
documented chronic quantitated exposure to VC and who carried
the diagnosis of HCC. All patients had received financial compen-
sation for their work-related impairment due to the proven rela-
tionship between work (VC exposure) and occurrence of disease
(primary tumour of the liver). All 18 patients lacked other discern-
able risk factors for developing liver cirrhosis and/or HCC. In our
series, an important argument for an association of VC and HCC is
the absence of other known risk factors in the examined patients.
Hepatitis B- or C-virus infection were ruled out serologically and
also immunohisto-chemically. Drugs, metabolic disorders or
autoimmune chronic hepatitis were excluded by laboratory investi-
gation and careful clinical history. Ethanol abuse could not be
completely evaluated in these patients; however, the absence of
histological features of heavy chronic alcoholism (Mallory bodies,
pericellular fibrosis, severe steatosis, alcoholic hepatitis) argue
against a significant impact of ethanol consumption in the aeti-
ology of HCC in these patients. The 3 patients with concomitant
liver cirrhosis exhibited no classical features of alcohol-induced
cirrhosis. Mild to moderate alcohol intake may be a potential
cocarcinogenic factor in VC-associated HCC but we present no
evidence for or against that argument. In Western countries, only
10–20% of all HCCs arise in non-cirrhotic livers (Tannapfel et al,
1999c). In contrast, only 3 of our patients had a concomitant liver
cirrhosis, a fact further supporting VC as the likely carcinogen and
again ruling out the classical risk factors for the development of
HCCs. 
In our series, the average duration of exposure and the amount
of exposure was 245 months and 8880 ppm years, respectively,
which corresponds with the current literature (Marion et al, 1996).
Tumour No 9
p16 methylated
Tumour No 10
p16 wild type
A B
Figure 2 Immunostaining of p16 protein in hepatocellular carcinoma. (A) Patient No 9 (same patients as in Figure 1 B) with a methylated p16 gene. Complete
loss of p16 expression. (B) Immunohistochemical staining of p16 in a moderately differentiated hepatocellular carcinoma without p16 methylation. 
Strong nuclear positivity of the tumour cells (brown reaction product). (Original magnification ´ 40) 988 M Weihrauch et al 
British Journal of Cancer (2001) 84(7), 982–989 © 2001 Cancer Research Campaign
The observed mean latency period between first VC exposure and
the initial diagnosis of HCC was 18 years (range 10 to 25 years)
which is significantly longer than the observed latency for VC-
associated LAS (Hollstein et al, 1994). One may speculate that VC
has a lesser carcinogenic effect on hepatocytes compared to
endothelial cells or that endothelial cells may have defects in their
DNA repair enzyme (Barbin et al, 1997; Marion, 1998). In contrast
to VC-induced LAS, which has a specific mutation pattern of the
K-ras-2 oncogene as described by Marion (1998), there remains a
lack of data concerning mutations in VC-associated HCC. We
therefore performed sequencing analysis of the K-ras-2 gene in
order to investigate a possible link between carcinogen exposure
and cancer. In our study, we found a high prevalence of G ® A
point mutations within codon 12 and 13. All 3 K-ras-2 mutations
occurring in non-neoplastic liver tissue were G ® A point muta-
tions as well. In contrast, G ® A mutations were found in one case
of the control group. This supports the data from ras mutations
studies in LAS of VC-exposed workers, where 83% of the tumours
were found to contain G ® A point mutations at codon 13.
Exposure to VC produced a similar mutation pattern with G:C ®
A:T point mutations at codon 61 of the N-ras gene in liver tumours
in Sprague-Dawley rats (Froment et al, 1994; Boivin-Angele,
2000). Collectively, these observations suggest that VC induces
a high frequency G:C ® A:T point mutations. The carcinogenic
metabolite of VC, chloroethylene oxide (Przygodzki et al, 1997;
Roy et al, 1998; Barbin, 1999) and a major promutagenic DNA
adduct of vinyl chloride, N2,3-ethenoguanine (Dogliotti et al,
1998), produce these same mutations. 
Ras oncogene mutations are frequently found in chemically
induced HCC in experimental animals (Chao et al, 1999; Boivin-
Angele et al, 2000; Xia et al, 1998), in contrast the frequency of
ras mutations in human HCC is much less. To date, there are few
studies on the prevalence of ras mutations in sporadic HCC
of various aetiologies. In a series of 19 sporadic HCCs, mutations
of the N-ras gene were found in about 16% (Challen et al, 1992).
However, the authors analysed the ras mutation status using PCR-
based mutation-specific oliginucleotide analyses and did not
perform DNA sequencing which may led to an underestimation
of the mutation rate. We utilized microdissection of our lesions
followed by very sensitive PCR methods which detect one mutated
K-ras codon 12 or 13 allele in the presence of 10 000–100 000
copies of the wild-type allele (Norheim Andersen et al, 1996). In
our control series of HCC in patients without VC exposure, we
could detect specific K-ras-2 mutations in about 15%. Further
studies of sporadic HCC are currently in progress to search for the
prevalence of K-ras-2 mutations in a large number of patients. 
Our data show a high frequency of p16 hypermethylation in
HCC which supports recent data published by the literature
(Matsuda et al, 1999). De novo hypermethylation of p16 is
reported to be the most common mechanism for inactivation of
this cell-cycle inhibitor (Matsuda et al, 1999). Nearly all carci-
nomas harbouring K-ras-2 mutations subsequently contained p16
methylation in our data. Overexpression of the p16 gene blocks S-
phase progression of the cell cycle and inhibits ras-induced cell
proliferation (Serrano et al, 1997). Oncogenic ras can transform
most immortal rodent cells to a tumourigenic state (Serrano et al,
1995). In contrast, expression of oncogenic ras in primary human
or rodent cells results in a permanent G1 arrest which is accompan-
ied by accumulation of p53 or p16 (Pantoja and Serrano, 1999).
However, transformation of primary cells by ras requires either a
cooperating oncogene or the inactivation of tumour suppressors
such as p53 or p16 (Serrano et al, 1997). One may speculate, that
inactivation of p16 releases cells from ras-induced G1 arrest and
allow them to enter the cell cycle. These data imply that aberrant
expression of p16 and ras mutation represent fundamental defects
in cell cycle regulation and together may play an important role in
the pathogenesis of HCC. 
In summary, our study is the first to characterize the K-ras-2
gene mutation in VC-associated HCCs. The mutation spectrum we
found with a high prevalence of G ®A point mutations even in adja-
cent non-neoplastic liver tissue of patients exposed to VC supports
those reported for the carcinogenic metabolites of VC. Our findings
of a strong correlation between p16 methylation and the K-ras-2
mutation in a given tumour could indicate a close molecular link
between K-ras-2 and p16 genes in HCCs. 
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